What’s Going On With Celcuity Stock On Tuesday?

Celcuity Inc. (NASDAQ:CELC) on Tuesday reported detailed efficacy and safety findings from the PIK3CA-mutated cohort of its Phase 3 VIKTORIA-1 trial. Gedatolisib Outperformed Comparator Regimen According to the company, the gedatolisib-triplet regimen delivered a...